These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38222314)
1. Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma. Xu W; Lu J; Tian X; Ye S; Wei S; Wang J; Anwaier A; Qu Y; Liu W; Chang K; Zhang H; Ye D MedComm (2020); 2024 Jan; 5(1):e461. PubMed ID: 38222314 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. Xu W; Ma C; Liu W; Anwaier A; Tian X; Shi G; Qu Y; Wei S; Zhang H; Ye D Cancer Immunol Immunother; 2022 Aug; 71(8):1923-1935. PubMed ID: 35043231 [TBL] [Abstract][Full Text] [Related]
8. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma. Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353 [TBL] [Abstract][Full Text] [Related]
10. Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring. Berthe J; Poudel P; Segerer FJ; Jennings EC; Ng F; Surace M; Andoni A; Testori M; Saraiya M; Vuko M; Hessel H; Heininen-Brown M; Blando J; Jones EV; Willis SE; Galon J; van de Ven R; de Gruijl TD; Angell HK Front Immunol; 2024; 15():1422206. PubMed ID: 39376565 [TBL] [Abstract][Full Text] [Related]
11. Lymphocyte Function in Tertiary Lymphoid Structures Predicts Hepatocellular Carcinoma Outcome. Li J; Xu H; Han J; Sun P; Zhang X; Wang H; Bian T; Xu Q; Ji J; Huang J Lab Invest; 2024 Nov; 104(11):102144. PubMed ID: 39343010 [TBL] [Abstract][Full Text] [Related]
12. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic responders. Sidiropoulos DN; Shin SM; Wetzel M; Girgis AA; Bergman D; Danilova L; Perikala S; Shu DH; Montagne JM; Deshpande A; Leatherman J; Dequiedt L; Jacobs V; Ogurtsova A; Mo G; Yuan X; Lvovs D; Stein-O'Brien G; Yarchoan M; Zhu Q; Harper EI; Weeraratna AT; Kiemen AL; Jaffee EM; Zheng L; Ho WJ; Anders RA; Fertig EJ; Kagohara LT bioRxiv; 2024 Sep; ():. PubMed ID: 39386736 [TBL] [Abstract][Full Text] [Related]
13. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS Front Immunol; 2021; 12():793964. PubMed ID: 34987518 [TBL] [Abstract][Full Text] [Related]
14. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma. Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y Front Immunol; 2023; 14():1096220. PubMed ID: 36776859 [TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma. Yao Y; Xuan H; Wang J; Gong L; Gao W Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074 [TBL] [Abstract][Full Text] [Related]
16. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953 [TBL] [Abstract][Full Text] [Related]
17. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486 [TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures' pattern and prognostic value in primary adenocarcinoma of jejunum and ileum. Deng M; Liu X; Jiang Y; Luo R; Xu L; Zhang X; Su J; Xu C; Hou Y World J Surg Oncol; 2024 Sep; 22(1):261. PubMed ID: 39350287 [TBL] [Abstract][Full Text] [Related]
19. Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma. Zhang T; Lei X; Jia W; Li J; Nie Y; Mao Z; Wang Y; Tao K; Song W Cancer Med; 2023 Feb; 12(3):3068-3078. PubMed ID: 36082777 [TBL] [Abstract][Full Text] [Related]
20. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma. Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]